Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Swapna Verma

Showing results (121-130 of 151) with videos related to

Pageof 16
Sort By:
International Journal of Environmental Research and Public Health|August 6, 2020
Smoking and Mental Illness: Prevalence, Patterns and Correlates of Smoking and Smoking Cessation among Psychiatric PatientsP V Asharani, Vanessa Ai Ling Seet, Edimansyah Abdin, et al.
Schizophrenia Research|February 22, 2018
Clinical trajectories in the ultra-high risk for psychosis populationAndrea Polari, Suzie Lavoie, Hok-Pan Yuen, et al.
Early Intervention in Psychiatry|August 18, 2015
NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disordersConnie Markulev, Patrick D McGorry, Barnaby Nelson, et al.
The Australian and New Zealand Journal of Psychiatry|August 26, 2025
Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO studyMonika Schlögelhofer, Ashleigh Lin, Connie Markulev, et al.
JAMA Psychiatry|November 29, 2016
Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical TrialPatrick D McGorry, Barnaby Nelson, Connie Markulev, et al.
Biological Psychiatry|November 7, 2019
The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for PsychosisG Paul Amminger, Barnaby Nelson, Connie Markulev, et al.
Schizophrenia Bulletin Open|August 15, 2024
Distress Related to Attenuated Psychotic Symptoms: Static and Dynamic Association With Transition to Psychosis, Nonremission, and Transdiagnostic Symptomatology in Clinical High-Risk Patients in an International Intervention TrialBarnaby Nelson, Hok Pan Yuen, G Paul Amminger, et al.
Frontiers in Psychiatry|June 28, 2019
Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical TrialMaximus Berger, Barnaby Nelson, Connie Markulev, et al.
Frontiers in Psychiatry|June 30, 2020
Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical TrialMaximus Berger, Barnaby Nelson, Connie Markulev, et al.
Schizophrenia Research|December 19, 2018
Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trialLuke K Bolt, G Paul Amminger, John Farhall, et al.
Pageof 16

Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
International Journal of Environmental Research and Public Health|August 6, 2020
Smoking and Mental Illness: Prevalence, Patterns and Correlates of Smoking and Smoking Cessation among Psychiatric PatientsP V Asharani, Vanessa Ai Ling Seet, Edimansyah Abdin, et al.
Schizophrenia Research|February 22, 2018
Clinical trajectories in the ultra-high risk for psychosis populationAndrea Polari, Suzie Lavoie, Hok-Pan Yuen, et al.
Early Intervention in Psychiatry|August 18, 2015
NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disordersConnie Markulev, Patrick D McGorry, Barnaby Nelson, et al.
The Australian and New Zealand Journal of Psychiatry|August 26, 2025
Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO studyMonika Schlögelhofer, Ashleigh Lin, Connie Markulev, et al.
JAMA Psychiatry|November 29, 2016
Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical TrialPatrick D McGorry, Barnaby Nelson, Connie Markulev, et al.
Biological Psychiatry|November 7, 2019
The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for PsychosisG Paul Amminger, Barnaby Nelson, Connie Markulev, et al.
Schizophrenia Bulletin Open|August 15, 2024
Distress Related to Attenuated Psychotic Symptoms: Static and Dynamic Association With Transition to Psychosis, Nonremission, and Transdiagnostic Symptomatology in Clinical High-Risk Patients in an International Intervention TrialBarnaby Nelson, Hok Pan Yuen, G Paul Amminger, et al.
Frontiers in Psychiatry|June 28, 2019
Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical TrialMaximus Berger, Barnaby Nelson, Connie Markulev, et al.
Frontiers in Psychiatry|June 30, 2020
Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical TrialMaximus Berger, Barnaby Nelson, Connie Markulev, et al.
Schizophrenia Research|December 19, 2018
Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trialLuke K Bolt, G Paul Amminger, John Farhall, et al.
Pageof 16